Gregory T Wurz Selected Research

L-BLP25

6/2014	Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model.
1/2014	Tecemotide: an antigen-specific cancer immunotherapy.
10/2013	Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy.
3/2013	Antitumor effects of L-BLP25 antigen-specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model.
11/2012	L-BLP25 vaccine plus letrozole for breast cancer: Is translation possible?
5/2012	L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gregory T Wurz Research Topics

Disease

13	Neoplasms (Cancer) 01/2017 - 01/2005
9	Breast Neoplasms (Breast Cancer) 11/2014 - 07/2002
7	Atrophy 11/2014 - 11/2005
4	Dyspareunia 01/2017 - 09/2013
4	Lung Neoplasms (Lung Cancer) 07/2015 - 03/2013
4	Carcinoma (Carcinomatosis) 10/2013 - 01/2005
4	Osteoporosis 09/2013 - 07/2002
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2014 - 03/2013
2	Carcinogenesis 03/2013 - 01/2005
1	Melanoma (Melanoma, Malignant) 01/2016
1	Atrophic Vaginitis 11/2014
1	Urinary Bladder Neoplasms (Bladder Cancer) 10/2013
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2013
1	Transitional Cell Carcinoma 10/2013
1	Chronic Disease (Chronic Diseases) 09/2013
1	Inflammation (Inflammations) 03/2013
1	Thromboembolism 01/2012
1	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2005
1	Vaginal Discharge 01/2003
1	Hot Flashes 01/2003
1	Cardiovascular Diseases (Cardiovascular Disease) 07/2002

Drug/Important Bio-Agent (IBA)

12	OspemifeneIBA 01/2017 - 07/2002
8	Tamoxifen FDA LinkGeneric 11/2014 - 07/2002
7	Selective Estrogen Receptor Modulators (SERM)IBA 11/2014 - 07/2002
6	L-BLP25IBA 06/2014 - 05/2012
5	CytokinesIBA 01/2017 - 03/2013
5	Estrogens (Estrogen)FDA Link 11/2014 - 01/2012
4	AntigensIBA 01/2017 - 03/2013
4	Estrogen ReceptorsIBA 01/2017 - 01/2012
3	VaccinesIBA 01/2016 - 05/2012
3	Cisplatin (Platino)FDA LinkGeneric 07/2015 - 06/2014
3	Toremifene (Fareston)FDA Link 01/2014 - 07/2002
3	Raloxifene Hydrochloride (Evista)FDA Link 11/2005 - 07/2002
2	Mucin-1 (CA 15-3 Antigen)IBA 06/2014 - 10/2013
2	CarcinogensIBA 10/2013 - 03/2013
2	LipidsIBA 09/2013 - 07/2002
2	Letrozole (Femara)FDA LinkGeneric 11/2012 - 05/2012
2	LY 353381 (LY353381)IBA 01/2003 - 07/2002
1	Peptides (Polypeptides)IBA 01/2017
1	Cancer VaccinesIBA 01/2017
1	AntibodiesIBA 01/2016
1	Monoclonal AntibodiesIBA 01/2016
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2016
1	LigandsIBA 07/2015
1	MicroRNAs (MicroRNA)IBA 07/2015
1	DNA AdductsIBA 04/2015
1	PlatinumIBA 04/2015
1	ImmunosorbentsIBA 06/2014
1	EnzymesIBA 06/2014
1	ButylhydroxybutylnitrosamineIBA 10/2013
1	hydroxide ionIBA 10/2013
1	Protein Subunit VaccinesIBA 10/2013
1	Interferon-gamma (Interferon, gamma)IBA 10/2013
1	Interleukin-4 (Interleukin 4)IBA 10/2013
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 03/2013
1	Urethane (Ethyl Carbamate)IBA 03/2013
1	MucinsIBA 05/2012
1	2-methylcyclopentadienyl manganese tricarbonyl (MMT)IBA 05/2012
1	Pharmaceutical PreparationsIBA 01/2012
1	4-hydroxyospemifeneIBA 01/2012
1	Anticarcinogenic AgentsIBA 01/2006
1	idoxifeneIBA 07/2002
1	droloxifeneIBA 07/2002
1	LasofoxifeneIBA 07/2002

Therapy/Procedure

5	Drug Therapy (Chemotherapy) 01/2016 - 03/2013
5	Immunotherapy 01/2016 - 03/2013
5	Therapeutics 06/2014 - 01/2003
3	Chemoradiotherapy 07/2015 - 10/2013
2	Radiotherapy 07/2015 - 06/2014
1	Microspheres (Microsphere) 10/2013
1	Intraperitoneal Injections 03/2013
1	Chemoprevention 01/2005
1	Transplantation 01/2005